Trial Profile
A Study to Evaluate the Potential in Vivo Effects of Fingolimod on Circulating CD1c+ Conventional Dendritic Cells in Patients with Multiple Sclerosis (MS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Dec 2015
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 18 Dec 2015 New trial record